Treatment outcomes among MDR/RR TB patients registered in Zimbabwe between 2010 and 2015, stratified by year of treatment commencement.

Clinical characteristics of MDR/RR-TB patients at baseline and/or during MDR-TB initiated on treatment in Zimbabwe, 2010–2015.

Clinical characteristics of MDR/RR-TB patients at baseline and/or during MDR-TB initiated on trea

End of Intensive phase treatment outcomes of hospitalized MDR–TB patients in Nigeria July 2010 – October, 2012.

End of Intensive phase treatment outcomes of hospitalized MDR–TB patients in Nigeria July 2010 –

Radiographic and Microbiologic Predictors of Treatment Outcomes in Patients Treated with a Shortened All-Oral Regimen for Multidrug- or Rifampicin-Resistant Tuberculosis (MDR/RR-TB) in Lesotho

Abstract Background Shortened, all-oral regimens endorsed by the WHO have improve

Treatment outcomes of patients with MDR-TB treated at 4 decentralised sites in KwaZulu-Natal, South Africa^*.

Data are number (%), unless otherwise indicated.

*Treatment outcome definitions used are WH

Africa — WHO GHO: Confirmed cases of RR-/MDR-TB

Indicator code: TB_rr_mdr HuggingFace slug: electricsheepafrica/africa-who-confirmed-cases-of-rr-mdr

MDR-TB patients Data in the six geopolitical zones of Nigeria from January 2013 to December 2017 with treatment outcomes

The aim of the study was to determine the rate of distribution, risk factors and treatment outcomes